Chansu Injection Enhances Erlotinib's Effect in Pancreatic Cancer
Author Information
Author(s): Guo Yanli, Jin Yu, Gao Jie, Wang Ding, Wang Yanming, Shan Liya, Yang Mengyu, Li Xinzhi, Ma Ketao
Primary Institution: Shihezi University School of Medicine
Hypothesis
This study aimed to elucidate the antitumor effects and pathways associated with Chansu injection in pancreatic cancer.
Conclusion
Chansu injection enhances the antitumor effects of erlotinib by modulating the KRAS pathway in pancreatic cancer treatment.
Supporting Evidence
- Chansu injection significantly inhibited the proliferation and migration of pancreatic cancer cells.
- CSI treatment induced G2/M phase arrest in pancreatic cancer cells.
- CSI reduced the expression of p-EGFR, KRAS, and p-ERK1/2 in treated cells.
- The combination of CSI and erlotinib showed a synergistic effect in reducing tumor growth in animal models.
- CSI did not cause detectable toxicity in renal, cardiac, or hepatic tissues at therapeutic doses.
Takeaway
Chansu injection helps make a cancer drug called erlotinib work better against pancreatic cancer by blocking a bad protein called KRAS.
Methodology
The study used network pharmacology, bioinformatics, MTT assays, colony-formation assays, migration assays, flow cytometry, and animal experiments to evaluate the effects of Chansu injection on pancreatic cancer cells.
Limitations
The study acknowledges the need for further investigation into the metabolism and distribution of Chansu in vivo.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website